Food-derived bioactives as potential regulators of the IL-12/IL-23 pathway implicated in inflammatory bowel diseases

Xavier, 2007, Unravelling the pathogenesis of inflammatory bowel disease, Nature, 448, 427, 10.1038/nature06005 Hue, 2006, Interleukin-23 drives innate and T cell-mediated intestinal inflammation, J. Exp. Med., 203, 2473, 10.1084/jem.20061099 Uhlig, 2006, Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology, Immunity, 25, 309, 10.1016/j.immuni.2006.05.017 Roberts, 2007, IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease, Am. J. Gastroenterol., 102, 2754, 10.1111/j.1572-0241.2007.01525.x Einarsdottir, 2009, IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease, BMC Med. Genet., 10, 8, 10.1186/1471-2350-10-8 Bamias, 2005, New concepts in the pathophysiology of inflammatory bowel disease, Ann. Intern. Med., 143, 895, 10.7326/0003-4819-143-12-200512200-00007 Shteyer, 2008, Novel therapeutic modalities in pediatric inflammatory bowel disease, Isr. Med. Assoc. J., 10, 816 Kornman, 2007, Interleukin-1 genotype-selective inhibition of inflammatory mediators by a botanical: a nutrigenetics proof of concept, Nutrition, 23, 844, 10.1016/j.nut.2007.08.005 Philpott, 2007, Cell culture models in developing nutrigenomics foods for inflammatory bowel disease, Mutat. Res., 622, 94, 10.1016/j.mrfmmm.2007.04.013 Parham, 2002, A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R, J. Immunol., 168, 5699, 10.4049/jimmunol.168.11.5699 Oppmann, 2000, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, 13, 715, 10.1016/S1074-7613(00)00070-4 Murphy, 2003, Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation, J. Exp. Med., 198, 1951, 10.1084/jem.20030896 Langrish, 2005, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J. Exp. Med., 201, 233, 10.1084/jem.20041257 Hori, 1987, Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus, Blood, 70, 1069, 10.1182/blood.V70.4.1069.1069 Calixto, 2004, Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules, Planta Med., 70, 93, 10.1055/s-2004-815483 Gremy, 2006, Caffeic acid phenethyl ester modifies the Th1/Th2 balance in ileal mucosa after gamma-irradiation in the rat by modulating the cytokine pattern, World J. Gastroenterol., 12, 4996, 10.3748/wjg.v12.i31.4996 Calder, 2008, Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases, Mol. Nutr. Food Res., 52, 885, 10.1002/mnfr.200700289 Dobryniewski, 2007, Biology of essential fatty acids (EFA), Przegl. Lek., 64, 91 Young, 1998, Effect of linoleic acid on endothelial cell inflammatory mediators, Metabolism, 47, 566, 10.1016/S0026-0495(98)90241-4 Swain, 1985, Salicylates in foods, J. Am. Diet. Assoc., 85, 950, 10.1016/S0002-8223(21)03743-3 Egan, 1998, Drug therapy of inflammatory bowel disease, Drugs Today, 34, 431, 10.1358/dot.1998.34.5.485242 Bustin, 2009, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments, Clin. Chem., 55, 611, 10.1373/clinchem.2008.112797 Breslin, 2005, LY294002 and rapamycin co-operate to inhibit T-cell proliferation, Br. J. Pharmacol., 144, 791, 10.1038/sj.bjp.0706061 Aggarwal, 2003, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17, J. Biol. Chem., 278, 1910, 10.1074/jbc.M207577200 Weaver, 2007, IL-17 family cytokines and the expanding diversity of effector T cell lineages, Annu. Rev. Immunol., 25, 821, 10.1146/annurev.immunol.25.022106.141557 Abdalla, 2003, Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR, Scand. J. Immunol., 58, 601, 10.1111/j.1365-3083.2003.01348.x Hayden, 2006, NF-kappaB and the immune response, Oncogene, 25, 6758, 10.1038/sj.onc.1209943 Yin, 1998, The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-beta, Nature, 396, 77, 10.1038/23948 Bailon, 2007, The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition, Biochem. Pharmacol., 74, 1496, 10.1016/j.bcp.2007.07.026 Navarro-Peran, 2008, The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-kappaB suppression, Inflamm. Res., 57, 472, 10.1007/s00011-008-8013-x Gorjao, 2007, Regulation of interleukin-2 signaling by fatty acids in human lymphocytes, J. Lipid Res., 48, 2009, 10.1194/jlr.M700175-JLR200 Prabhakar, 2005, Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects, DNA Cell Biol., 24, 410, 10.1089/dna.2005.24.410 Blackwell, 1997, The role of nuclear factor-kappa B in cytokine gene regulation, Am. J. Respir. Cell. Mol. Biol., 17, 3, 10.1165/ajrcmb.17.1.f132 Abboud, 2008, Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis, Eur. J. Pharmacol., 579, 411, 10.1016/j.ejphar.2007.10.053 Fitzpatrick, 2001, Caffeic acid phenethyl ester, an inhibitor of nuclear factor-kappaB, attenuates bacterial peptidoglycan polysaccharide-induced colitis in rats, J. Pharmacol. Exp. Ther., 299, 915 Haddad, 2001, Nuclear factor-kappab blockade attenuates but does not abrogate lipopolysaccharide-dependent tumor necrosis factor-alpha biosynthesis in alveolar epithelial cells, Biochem. Biophys. Res. Commun., 285, 267, 10.1006/bbrc.2001.5172 Natarajan, 1996, Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B, Proc. Natl. Acad. Sci. U.S.A., 93, 9090, 10.1073/pnas.93.17.9090 Haddad, 2002, Cytokines and related receptor-mediated signaling pathways, Biochem. Biophys. Res. Commun., 297, 700, 10.1016/S0006-291X(02)02287-8 Yang, 2001, The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6, Mol. Pharmacol., 60, 528 Komatsu, 2003, Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress, Free Radic. Biol. Med., 34, 1006, 10.1016/S0891-5849(03)00027-3 Moon, 2005, Epigallocatechin-3-gallate suppresses galactose-alpha1, 4-galactose-1beta,4-glucose ceramide expression in TNF-alpha stimulated human intestinal epithelial cells through inhibition of MAPKs and NF-kappaB, J. Korean Med. Sci., 20, 548, 10.3346/jkms.2005.20.4.548 Lytle, 2005, The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency, Inflamm. Bowel Dis., 11, 231, 10.1097/01.MIB.0000160805.46235.eb Sanchez-Hidalgo, 2007, Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats, Eur. J. Pharmacol., 562, 247, 10.1016/j.ejphar.2007.01.047 Katayama, 2003, A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model, Gastroenterology, 124, 1315, 10.1016/S0016-5085(03)00262-2 Ricote, 1998, The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation, Nature, 391, 79, 10.1038/34178 Jiang, 1998, PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, Nature, 391, 82, 10.1038/35154 Takagi, 2002, Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade, Redox Rep., 7, 283, 10.1179/135100002125000802 Rousseaux, 2005, Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma, J. Exp. Med., 201, 1205, 10.1084/jem.20041948 Ye, 2008, Regulation of PPARgamma function by TNF-alpha, Biochem. Biophys. Res. Commun., 374, 405, 10.1016/j.bbrc.2008.07.068